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Aspirin is an effective antiplatelet agent for preventing
important clinical complications of atherothrombosis (1).
Among 29,652 high-vascular-risk patients randomly allo-
cated to long-term aspirin therapy, the rate of serious
vascular events (nonfatal myocardial infarction, nonfatal
stroke, or vascular death) after about two years was 12.9%,
compared with 16.0% among 29,743 patients allocated to
control (1). This is an odds reduction of 23% (standard
deviation 2), a relative risk reduction of 19%, and an
absolute risk reduction of 3.1% over two years, or 1.5% per
year (1). Therefore, aspirin fails to prevent more than
four-fifths (81%) of recurrent serious vascular events among
high-risk patients, and one in eight high-risk patients
(12.9%) experiences a recurrent vascular event in the next
two years despite taking aspirin.
See page 961
There are several reasons why aspirin may not be totally
effective in preventing recurrent serious vascular events, and
these are listed in Table 1. One possible explanation that has
recently attracted great interest is that some patients are
resistant to the antiplatelet effects of aspirin. The term
“aspirin resistance” has evolved to describe the failure of
aspirin to produce an expected response on one or more
laboratory measures of platelet activation and aggregation.
As many as half of the population have thus been defined as
aspirin resistant (2–8). However, laboratory definitions of
“aspirin resistance” have varied according to the platelet
function tests used, and no study has prospectively validated
conventional platelet aggregometry as an independent pre-
dictor of subsequent serious vascular events.
In this issue of the Journal, Gum et al. (9) provide the first
reliable evidence that aspirin resistance, as diagnosed by lack
of suppression of optical platelet aggregation, correlates
with confirmed (not just presumed) clinical unresponsive-
ness. In 2001 they had reported that 18 (5.5%, 95%
confidence interval [CI]: 3.3% to 8.6%) of 325 patients with
a prior history of coronary or cerebral vascular disease were
aspirin resistant (8). Aspirin resistance was defined as the
failure of aspirin 325 mg/day, given for a minimum of seven
days before testing, to suppress agonist-induced platelet
aggregation, as measured by optical platelet aggregometry.
The cutoff for the diagnosis of aspirin resistance was derived
from screening 40 in-house normal samples, but details as to
how this cutoff was chosen were not provided. Gum et al.
(9) now report the two-year follow-up of this cohort of
patients. Follow-up was complete for 316 (97%) of the 326
patients included in this cohort, 16 of the 17 aspirin-
resistant patients, and 300 of the 309 nonaspirin-resistant
patients. A serious vascular event occurred in 34 patients
(10%), including 4 of the 17 (23.5%, 95% CI: 6.8% to
49.9%) patients who were aspirin resistant and 30 of the 309
patients (9.7%, 95% CI: 6.6% to 13.6%) patients who were
not aspirin resistant. Univariate analysis revealed that
aspirin-resistant patients had a 3.1-fold excess hazard of
serious vascular events (hazard ratio 3.1, 95% CI: 1.1 to 8.9)
compared with nonaspirin-resistant patients. After adjust-
ing for 12 potential prognostic factors, multivariate analysis
indicated that aspirin resistance was associated with a
4.1-fold excess adjusted hazard of serious vascular events
(hazard ratio 4.1, 95% CI: 1.4 to 12.1), independent of age,
gender, and conventional vascular risk factors.
The work of Gum et al. (9) indicates that failure to
achieve an anticipated effect of aspirin on a laboratory
measure of platelet aggregation, which is present in about 1
in 20 high-risk patients, is an independent predictor of
future risk of serious vascular events. However, their esti-
mate of the magnitude of hazard is imprecise because the
number of outcome events was small. The 95% CIs are
consistent with an excess hazard as low as 1.4-fold and as
much as 12-fold.
However, the work of Gum et al. (9) raises other
questions. Is the definition of aspirin resistance now stan-
dardized, valid, and reliable? Are the results of this study
reproducible, and can they be generalized to other labora-
tories and other patients? Is there now a role of screening for
aspirin resistance in clinical practice? If so, what are the
therapeutic implications of a diagnosis of aspirin resistance?
Is the definition of aspirin resistance now standardized,
valid, and reliable, and are the results of this study
generalizable? The definition of aspirin resistance used by
Gum et al. (9) was based on the results of optical platelet
aggregometry. This has potentially important implications
for clinicians because, unlike many other laboratory mea-
sures of platelet function, optical platelet aggregometry is
widely available and is routinely used to assess platelet
function and to measure the antiplatelet effects of aspirin.
However, there are various other techniques to measure
platelet aggregometry, including whole-blood aggregometry
(5,6), the platelet aggregate ratio (7), and the platelet
reactivity index, a measure of in vivo platelet aggregation
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induced during the process of blood collection (2,10,11).
These techniques collectively identify an inadequate re-
sponse to aspirin in 5% to 60% of patients with athero-
thrombosis of the cerebral, coronary, or peripheral circula-
tions (2–11). It is difficult to assess which technique is the
most accurate and valid measure of aspirin resistance with-
out direct comparisons of their clinical relevance (such as
capacity to discriminate patients at risk of recurrent vascular
events). Timing may also be an important determinant of
the validity of tests of aspirin resistance because several serial
studies of platelet aggregometry suggest that the antiplatelet
effects of aspirin vary over time (4,6,12). By contrast, other
studies have found suppression of platelet aggregation in all
patients tested (13,14) without attenuation of the antiplate-
let effect during 24 months of follow-up (14). These
divergent results most likely reflect differences in the defi-
nition of aspirin resistance as well as methodologic differ-
ences in the performance and interpretation of platelet
aggregometry studies among laboratories (15).
The PFA-100 (Dade Behring, Deerfield, Illinois) is a
semiautomated platelet function analyzer that has recently
been proposed as an alternative to conventional platelet
aggregometry to identify aspirin-resistant individuals (16).
It allows rapid assessment of platelet adhesion/aggregation
and is increasingly being used in clinical practice to screen
for inherited or acquired haemostatic disorders. However,
the PFA-100 does not provide a specific measure of the
antiplatelet effects of aspirin (17) and may lack sensitivity for
measuring the antiplatelet effects of low-dose aspirin (18).
Skin bleeding time has also been used to measure the
antiplatelet effects of aspirin (19,20), but it is a nonspecific
measure of platelet function, is operator dependent, and has
limited reproducibility.
Most recently, a continuous and graded association was
demonstrated between increasing levels of urinary 11-
dehydro thromboxane B2 and risk of future clinical events
(21). However, because the concentration of 11-dehydro
thromboxane B2 in the urine reflects both platelet and
nonplatelet sources of thromboxane generation, this may
not be a specific measure of the antiplatelet effects of aspirin.
Furthermore, the predictive value of 11-dehydro thrombox-
ane B2 concentrations in an individual patient has not been
demonstrated and requires further evaluation.
These data highlight the limitations of existing laboratory
measures of the antiplatelet effects of aspirin as well as the
need to develop a standardized definition of aspirin resis-
tance. A suitable definition of aspirin resistance should not
only incorporate an absent or attenuated laboratory response
to a therapeutic antiplatelet dose of aspirin (for example, at
least 75 mg/day for 5 days) in a compliant patient that
correlates significantly and independently with its effects in
preventing atherothrombotic vascular events; it also requires
a specific, accurate, and reproducible laboratory measure of
the antiplatelet effects of aspirin, the results of which can be
generalized to other laboratories and patients. None of the
currently available laboratory tests of the antiplatelet effects
of aspirin has yet been demonstrated to meet adequately
these criteria.
Is there now a role of screening for aspirin resistance in
clinical practice? Even if aspirin resistance could be de-
fined and reliably diagnosed by laboratory testing, screening
for aspirin resistance (in asymptomatic individuals, and
symptomatic patients who experience a thrombotic compli-
cation despite aspirin therapy) could still only be recom-
mended if the results of screening (positive and negative)
influenced clinical management (such as optimizing predic-
tion of risk of serious vascular event) or led to treatments
that improved patient outcome in a cost-effective manner.
What are the therapeutic implications of a diagnosis of
aspirin resistance? There are presently no specific treat-
ments for aspirin resistance. However, several strategies may
further reduce the risk of thrombotic complications in
patients who are prescribed aspirin for vascular prevention
(Table 1). First, the underlying cause of any vascular event
should be accurately diagnosed because between 5% and
40% of these events are not caused by atherothrombosis and
may require alternative or additional treatments (22). Sec-
ond, poor compliance or inadequate aspirin dosing (at least
75 mg/day appears to be optimal for long-term use [4])
should be considered as possible causes of thrombotic
complications. The 5% of patients that cannot tolerate
aspirin or are allergic to aspirin should be treated with the
adenosine diphosphate receptor antagonist clopidogrel (23).
Third, alternative antithrombotic strategies should be con-
sidered in patients who experience a thrombotic complica-
tion during aspirin therapy. Clopidogrel blocks pathways of
platelet activation and aggregation that cannot be blocked
by aspirin and should be considered as a substitute for, or
additional treatment to, aspirin. Clopidogrel is superior to
aspirin for the prevention of vascular events in a broad
category of high-risk vascular patients (23,24), whereas the
combination of clopidogrel plus aspirin is superior to aspirin
alone in patients with non–ST-segment elevation acute
coronary syndrome (25) or undergoing percutaneous coro-
nary intervention (26,27). The combination of dipyridamole
Table 1. Possible Mechanisms to Account for the Apparent
Failure of Aspirin to Protect Some High-Risk Individuals From
Recurrent Vascular Events
Cause Mechanism
Wrong diagnosis Nonatherothrombotic causes of vascular
disease
Not taking the drug Nonadherence to aspirin (poor compliance)
Insufficient drug Higher dose of aspirin required
Different pathway Alternative “upstream” pathways of platelet
activation that are not blocked by aspirin
Aspirin-insensitive thromboxane
biosynthesis
Drug interactions Drugs that interfere with the
antithrombotic effects of aspirin
Other predisposing factors Platelet glycoprotein polymorphisms
Increased platelet turnover states
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plus aspirin (28) or warfarin plus aspirin (29) may also
provide incremental benefit compared with aspirin alone.
There is now good evidence that a substantial proportion
of individuals treated with aspirin fail to achieve an antici-
pated response on commonly used laboratory measures of
the antiplatelet effects of aspirin. Further work is required to
standardize and validate laboratory tests of the antiplatelet
effects of aspirin and to identify therapeutic strategies that
can modify the results of these investigations and thereby
reduce the risk of future thrombotic complications. In the
meantime, however, clinicians should ensure the continued
use of aspirin in all eligible patients and a high level of
compliance with aspirin therapy in treated patients. Despite
the known limitations of aspirin, the appropriate use of this
simple, proven treatment will continue to prevent many
thousands of premature atherothrombotic vascular events
each year.
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